Clinical Trial Update: A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update announcing JNJ-89853413 for relapsed or refractory acute myeloid leukemia and myelodysplastic neoplasms, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• JNJ-89853413

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Leukemia, Myeloid, Acute, Myelodysplastic Neoplasms | Phase 1 | Status: RECRUITING